The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Reyal, Fabien ^a   Rouzier, Roman ^b,c   Depont Hazelzet, Berenice ^a   Bollet, Marc A ^a   Pierga, Jean Yves ^a   Alran, Severine ^a   Salmon, Remy J ^a   Fourchotte, Virginie ^a   Vincent Salomon, Anne ^a   Sastre Garau, Xavier ^a   Antoine, Martine ^b   Uzan, Serge ^b,c   Sigal Zafrani, Brigitte ^a   de Rycke, Yann ^a  

^a INSTITUT CURIE   (France)

^b HÔPITAL TENON   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; BREAST SURGERY; CALIBRATION; CANCER INVASION; CANCER PATIENT; DISTANT METASTASIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROMETASTASIS; MITOSIS INDEX; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME; BREAST TUMOR; CARCINOMA; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; STATISTICAL MODEL;

AGED; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SENTINEL LYMPH NODE BIOPSY;

EID: 79957846432     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020297     Document Type: Article

References (30)

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. (2000) Molecular portraits of human breast tumours. Nature 17;406 (6797): 747-752.
2. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, et al. (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10 (4): R65.
3. Weigelt B, Mackay A, A'hern R, Natrajan R, Tan DSP, Dowsett M, et al. (2010) Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 11 (4): 339-349.
4. Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M, et al. (2008) A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res 10 (6): R93.
5. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 15;11 (16): 5678-5685.
6. Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H, (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 1;28 (10): 1684-1691.
7. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, et al. (2008) Subtypes of Breast Cancer Show Preferential Site of Relapse. Cancer Research 1;68 (9): 3108-3114.
8. Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, et al. (2006) Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 20;24 (36): 5658-5663.
9. Lu X, Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL, (2008) Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat 108 (2): 191-201.
10. Crabb SJ, Cheang MCU, Leung S, Immonen T, Nielsen TO, Huntsman DD, et al. (2008) Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer 8 (3): 249-256.
11. Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F, (2008) Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum Pathol 39 (2): 167-174.
12. Van Calster B, Vanden Bempt I, Drijkoningen M, Pochet N, Cheng J, Van Huffel S, et al. (2009) Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive. Breast Cancer Res Treat 113 (1): 181-187.
13. Lee JH, Kim SH, Suh YJ, Shim BY, Kim HK, (2010) Predictors of Axillary Lymph Node Metastases (ALNM) in a Korean Population with T1-2 Breast Carcinoma: Triple Negative Breast Cancer has a High Incidence of ALNM Irrespective of the Tumor Size. Cancer Res Treat 42 (1): 30-36.
14. Kim M, Ro JY, Ahn S, Kim HH, Kim S, Gong G, (2006) Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37 (9): 1217-1226.
15. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, et al. (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 10;26 (14): 2373-2378.
16. Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H, (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 1;28 (10): 1684-1691.
17. Barth A, Craig PH, Silverstein MJ, (1997) Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer 15;79 (10): 1918-1922.
18. Fehm T, Maul H, Gebauer S, Scharf A, Baier P, Sohn C, et al. (2005) Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor. Strahlenther Onkol 181 (9): 580-586.
19. González-Vela MC, Garijo MF, Fernández FA, Buelta L, Val-Bernal JF, (1999) Predictors of axillary lymph node metastases in patients with invasive breast carcinoma by a combination of classical and biological prognostic factors. Pathol Res Pract 195 (9): 611-618.
20. Guarnieri A, Neri A, Correale PP, Lottini M, Testa M, Mariani F, et al. (2001) Prediction of lymph node status by analysis of prognostic factors and possible indications for elective axillary dissection in T1 breast cancers. Eur J Surg 167 (4): 255-259.
21. Olivotto IA, Jackson JS, Mates D, Andersen S, Davidson W, Bryce CJ, et al. (1998) Prediction of axillary lymph node involvement of women with invasive breast carcinoma: a multivariate analysis. Cancer 1;83 (5): 948-955.
22. Ravdin PM, De Laurentiis M, Vendely T, Clark GM, (1994) Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst 7;86 (23): 1771-1775.
23. Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne MP, (2000) Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg 191 (1): 1-6; discussion 6-8.
24. Yip CH, Taib NA, Tan GH, Ng KL, Yoong BK, Choo WY, (2009) Predictors of axillary lymph node metastases in breast cancer: is there a role for minimal axillary surgery? World J Surg 33 (1): 54-57.
25. Bader AA, Tio J, Petru E, Bühner M, Pfahlberg A, Volkholz H, et al. (2002) T1 breast cancer: identification of patients at low risk of axillary lymph node metastases. Breast Cancer Res Treat 76 (1): 11-17.
26. Fréneaux P, Nos C, Vincent-Salomon A, Genin P, Sigal-Zafrani B, Al Ghuzlan A, et al. (2002) Histological detection of minimal metastatic involvement in axillary sentinel nodes: a rational basis for a sensitive methodology usable in daily practice. Mod Pathol 15 (6): 641-646.
27. van Diest PJ, Matze-Cok E, Baak JP, (1991) Prognostic value of proliferative activity in lymph node metastases of patients with breast cancer. J Clin Pathol 44 (5): 416-418.
28. van Diest PJ, Baak JP, Matze-Cok P, Wisse-Brekelmans EC, van Galen CM, Kurver PH, et al. (1992) Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 23 (6): 603-607.
29. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 1;25 (1): 118-145.
30. Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, et al. (2005) Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 15;65 (20): 9155-9158.